President & Chief Executive Officer
Steven Kelly has been the President and CEO of CARISMA Therapeutics since February 2018. Before leading CARISMA, Mr. Kelly was the founding CEO of Pinteon Therapeutics, an early-stage Oncology, and CNS development company.
Prior to this, he held a number of leadership positions in the biotechnology industry including: CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen. Mr. Kelly holds a BS from the University of Oregon and an MBA from Cornell University.
Sector Focus Breakout: Life Science
Discover IP Group, Inc.’s Life Science portfolio, with updates from two growing companies, MOBILion Systems Inc. and Carisma Therapeutics, as well as an introduction to one of IP Group’s exciting early-stage projects from the University of Pennsylvania.